menu
    • menu

    Company profile for Momenta Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Momenta Pharmaceuticals is a biotechnology company with a validated, innovative scientific platform. We focus on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, while advancing our late stage biosimilar portfolio.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Momenta PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    301 Binney Street Cambridge, MA 02142
    Telephone
    Telephone
    7-491-9700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.momentapharma.com/home/default.aspx
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    J&J finds another path for Momenta drug in rare fetal disorder
    J&J finds another path for Momenta drug in rare fetal disorder

    07 Feb 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/jj-latest-data-nipocalimab-fetal-disorder-suggests-momenta-buy-may-pay

    James Waldron FIERCE BIOTECH
    07 Feb 2023
    Share Share
    J&J, Momenta Pharma file patent infringement lawsuit against Natco, Mylan
    J&J, Momenta Pharma file patent infringement lawsuit against Natco, Mylan

    26 May 2022

    // BUSINESS-STANDARD

    https://www.business-standard.com/article/companies/j-j-momenta-pharma-file-patent-infringement-lawsuit-against-natco-mylan-122052500935_1.html

    BUSINESS-STANDARD
    26 May 2022
    Share Share
    Provention hires 3rd exec as it awaits FDA meeting for lead drug
    Provention hires 3rd exec as it awaits FDA meeting for lead drug

    18 Nov 2021

    // K. LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/provention-bio-hires-third-exec-as-many-weeks-as-it-awaits-fda-meeting-for-rejected-drug

    K. LaHucik FIERCEBIOTECH
    18 Nov 2021
    Share Share
    J&J, free from rival bidders, made Momenta wait on $6.5B deal
    J&J, free from rival bidders, made Momenta wait on $6.5B deal

    03 Sep 2020

    // Nick Paul Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/j-j-free-from-rival-bidders-made-momenta-wait-6-5b-deal

    Nick Paul Taylor FIERCEBIOTECH
    03 Sep 2020
    Share Share
    Enthused by PhII autoimmune data, J&J kept Momenta waiting in $6.5B buyout
    Enthused by PhII autoimmune data, J&J kept Momenta waiting in $6.5B buyout

    02 Sep 2020

    // Amber Tong ENDPTS

    https://endpts.com/enthused-by-phii-autoimmune-data-jj-kept-momenta-waiting-in-the-lead-up-to-6-5b-buyout/

    Amber Tong ENDPTS
    02 Sep 2020
    Share Share
    Momenta Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
    Momenta Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN

    27 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/28/2068533/0/en/Momenta-Pharmaceuticals-Announces-FDA-Rare-Pediatric-Disease-Designation-for-Nipocalimab-in-HDFN.html#:~:text=(NASDAQ%3A%20MNTA)%20today%20announced,orphan%20drug%20designation%20in%20HDFN.

    GLOBENEWSWIRE
    27 Jul 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search